Genome editing has been a hot-button topic in recent years. With the rise of CRISPR technology in the news, this is not surprising for either scientists or investors.
https://www.pharmalive.com/wp-content/uploads/2023/03/womenwithglovesvial-lab.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-03-13 08:44:532023-03-13 08:57:09CRISPR/ViaCyte and Genprex vie for first diabetes gene therapy
